Corvus Pharmaceuticals, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 5 Aug 2026Changes to the board affect company leadership and decision-making at the highest level.
Stockholder votes show whether investors trust management's pay and strategic direction.
Positive drug trial results boost chances a new medicine reaches patients and generates revenue.
Quarterly earnings reports reveal whether the company is spending money wisely and progressing.
Quarterly earnings reports reveal whether the company is spending money wisely and progressing.
Board changes affect company leadership and who oversees management decisions.
A larger ability to raise cash lets the company fund drug development and operations longer.
Stocky reads Corvus Pharmaceuticals, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Corvus Pharmaceuticals, Inc.'s most recent tracked filing was a 8-K on 22 Jul 2026: Board director Ian T. Clark resigns after nine years.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 5 Aug 2026.